Bluejay Diagnostics (BJDX) Short-Term Debt issuances (2021)

Bluejay Diagnostics (BJDX) reported Short-Term Debt issuances of $725.0 for Q2 2021, up 107.46% sequentially from -$9725.0 in Q1 2021.

Bluejay Diagnostics (BJDX) Short-Term Debt issuances (2021) Analysis & Trends

Bluejay Diagnostics (BJDX) has 1 years of Short-Term Debt issuances data on file, last reported at $725.0 in Q2 2021.

For the quarter ending Q2 2021, Short-Term Debt issuances changed N/A year-over-year to $725.0; the trailing twelve-month figure through Dec 2021 stood at -$9000.0 (changed N/A YoY), and the FY2021 full-year result was -$9000.0, down 107.76% from the prior year.
Short-Term Debt issuances advanced to $725.0 in Q2 2021, from -$9725.0 in the prior quarter.
In the past five years, Short-Term Debt issuances ranged from a high of $725.0 in Q2 2021 to a low of -$9725.0 in Q1 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Short-Term Debt issuances (Qtr)
1	Abbott Laboratories	201.40 Bn	194.75 Bn	6.27 Bn	31.00 Mn
2	Stryker	122.29 Bn	119.41 Bn	3.81 Bn	-
3	Medtronic	105.01 Bn	96.40 Bn	6.41 Bn	-164.00 Mn
4	Boston Scientific	64.81 Bn	63.59 Bn	3.61 Bn	259.00 Mn
5	Edwards Lifesciences	55.28 Bn	51.60 Bn	1.29 Bn	-
6	Dexcom	29.06 Bn	27.94 Bn	750.30 Mn	-
7	Koninklijke Philips	29.02 Bn	25.93 Bn	2.07 Bn	12.88 Mn
8	GE HealthCare Technologies	28.27 Bn	26.20 Bn	1.98 Bn	-1.00 Mn
9	Smith & Nephew	25.80 Bn	25.22 Bn	-	-
10	Bluejay Diagnostics	2,754.24	2,754.24	-	-

Download Data